The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals Inc (NASDAQ:IDIX), and other violations of state law by the board of directors of Merck & Co., Inc. (“Merck”), in a transaction valued at approximately $3.85 billion. Idenix Pharmaceuticals Inc (NASDAQ:IDIX), weekly performance is 244.78%. On last trading day company shares ended up $23.79. Analysts mean target price for the company is $5.80. Idenix Pharmaceuticals Inc (NASDAQ:IDIX), distance from 50-day simple moving average (SMA50) is 307.27%.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI)‘s stock had its “buy” rating reiterated by stock analysts at Laidlaw in a report issued on Monday. They currently have a $15.00 target price on the stock. Laidlaw’s target price would suggest a potential upside of 50.00% from the stock’s previous close. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), fell 1.50% in last trading session and ended the day on $9.85. BDSI, Gross Margin is 92.10% and its return on assets is -81.90%. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), quarterly performance is -0.91%.
On June 05, 2014, InterMune Inc (NASDAQ:ITMN), again submitted the NDA for its lung disease drug, Esbriet. Esbriet is previously approved in the EU and acceptance in the U.S. would enhance sales of the drug heavily. Esbriet sales came in $70.3 million in 2013. Six month review would let the firm to release in the U.S. in the initial quarter of 2015, gave it gains FDA approval. Shares ticked up 0.4% after the news on Wednesday. InterMune Inc (NASDAQ:ITMN), shares moved up 1.29% in last trading session and was closed at $41.67, while trading in range of $41.08 -42.68. InterMune Inc (NASDAQ:ITMN),year to date (YTD) performance is 182.89%.
On June 05, 2014, EXACT Sciences Corporation (NASDAQ:EXAS), announced that the company will participate in the Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes, Calif. EXACT Sciences Corporation (NASDAQ:EXAS), ended the last trading day at $15.31. Company weekly volatility is calculated as 4.81% and price to cash ratio as 10.92. EXACT Sciences Corporation (NASDAQ:EXAS), showed a positive weekly performance of 14.25%.
Ophthotech Corp (NASDAQ:OPHT), major shareholder Svlsf Iv, Llc sold 1,966,935 shares of the company’s stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $42.54, for a total value of $83,673,414.90. Following the completion of the transaction, the insider now directly owns 84,325 shares in the company, valued at approximately $3,587,186. Ophthotech Corp (NASDAQ:OPHT), weekly performance is 16.01%. On last trading day company shares ended up $46.31. Analysts mean target price for the company is $63.25. Ophthotech Corp (NASDAQ:OPHT), distance from 50-day simple moving average (SMA50) is 34.01%.